title: The effect of cilostazol on right heart function and pulmonary pressure.
abstract: BACKGROUND
  Cilostazol is a PDE3 inhibitor and used to treat peripheral arterial disease. There are few reports on the influence of cilostazol on heart.
  
  
  OBJECTIVE
  The aim of this study was to assess this effect on right ventricular function and pulmonary artery pressure.
  
  
  METHODS
  Forty patients with normal left and right ventricular ejection fraction and mild or moderate pulmonary artery hypertension were enrolled in the study. Right ventricular function was assessed by tricuspid annular plane systolic excursion (TAPSE), fractional area change (FAC), tissue Doppler imaging (TDI), and two-dimensional speckle-tracking echocardiography (2D-STE) before and after oral administration of cilostazol. Also pulmonary artery pressure assessed before and after administration of cilostazol.
  
  
  RESULTS
  After cilostazol administration, there were significant increases in the TAPSE (1.9 ± 0.3 cm vs. 2.2 ± 0.3 cm, P < 0.001). Peak longitudinal strain (-18.7 ± 4.5% vs. -21.3  ± 3.7%, P = 0.001), isovolumetric acceleration (IVA) (176.6 ± 62.7 cm/sec(2) vs. 200.6 ± 61.9 cm/sec(2) , P = 0.025), right ventricular FAC increased significantly (37.6 ± 8.0% vs. 41.5 ± 8.9%, P < 0.001). Pulmonary artery pressure decreased significantly (39.9 ± 7.9 vs. 36.6 ± 5.5 mmHg, P = 0.001) after cilostazol administration.
  
  
  CONCLUSIONS
  Our study demonstrated that cilostazol improved right ventricular systolic function and reduced pulmonary artery pressure.
authors.affiliation: Department of Cardiology, Kartal Kosuyolu High Speciality Education and Research Hospital, Istanbul, Turkey.
authors.forename: Muslum
authors.initials: M
authors.lastname: Sahin
authors.forename: Elnur
authors.initials: E
authors.lastname: Alizade
authors.forename: Selcuk
authors.initials: S
authors.lastname: Pala
authors.forename: Gokhan
authors.initials: G
authors.lastname: Alici
authors.forename: Birol
authors.initials: B
authors.lastname: Ozkan
authors.forename: Taylan
authors.initials: T
authors.lastname: Akgun
authors.forename: Yunus
authors.initials: Y
authors.lastname: Emiroglu
authors.forename: Serdar
authors.initials: S
authors.lastname: Demir
authors.forename: Mehmet V
authors.initials: MV
authors.lastname: Yazicioglu
authors.forename: Mehmet M
authors.initials: MM
authors.lastname: Turkmen
mesh_terms: D000368:Aged; D000077407:Cilostazol; D065627:Familial Primary Pulmonary Hypertension; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D058987:Phosphodiesterase 3 Inhibitors / Q000494:pharmacology*; D011651:Pulmonary Artery / Q000187:drug effects / Q000502:physiology; D013777:Tetrazoles / Q000494:pharmacology* / Q000627:therapeutic use; D016278:Ventricular Function, Right / Q000187:drug effects*
chemical_list: D058987:Phosphodiesterase 3 Inhibitors; D013777:Tetrazoles; D000077407:Cilostazol
keywords: Cilostazol; right ventricular function and pulmonary artery pressure; strain